{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:45:56Z","timestamp":1783035956202,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clim.2023.109695","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:38:37Z","timestamp":1689813517000},"page":"109695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis"],"prefix":"10.1016","volume":"254","author":[{"given":"X. Rebecca","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumalai R.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J.F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Neighbors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2023.109695_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2023.109695_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102211","article-title":"Current advances in the treatment of systemic sclerosis","volume":"64","author":"Bukiri","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.clim.2023.109695_bb0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.clim.2023.109695_bb0020","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.clim.2023.109695_bb0025","first-page":"1215","article-title":"Biomarkers of skin and lung fibrosis in systemic sclerosis, expert rev","volume":"15","author":"Martinovic Kaliterna","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2023.109695_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.760776","article-title":"Longitudinal and comparative measures of serum chitotriosidase and YKL-40 in patients with idiopathic pulmonary fibrosis","volume":"13","author":"Majewski","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2023.109695_bb0035","article-title":"Osteopontin links myeloid activation and disease progression in systemic sclerosis","volume":"1","author":"Gao","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.clim.2023.109695_bb0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2023.109695_bb0045","first-page":"122","article-title":"The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review","volume":"31","author":"Muangchant","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2023.109695_bb0050","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/exd.13724","article-title":"CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis","volume":"27","author":"Taniguchi","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2023.109695_bb0055","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2021-220209","article-title":"Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis","volume":"80","author":"Gaydosik","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2023.109695_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/ker442","article-title":"Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease","volume":"51","author":"Hesselstrand","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2023.109695_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jdermsci.2018.02.001","article-title":"Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-beta signaling","volume":"90","author":"Kanaoka","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.clim.2023.109695_bb0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/jtd.2017.02.48","article-title":"Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease","volume":"9","author":"Yamakawa","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.clim.2023.109695_bb0075","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2665-9913(20)30385-4","article-title":"Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study","volume":"3","author":"Dobrota","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2023.109695_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207324","article-title":"Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: a cross-sectional study","volume":"13","author":"Juhl","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2023.109695_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2023.109695_bb0090","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2023.109695_bb0095","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2023.109695_bb0100","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40744-022-00444-x","article-title":"Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with Guselkumab treatment in a phase 3 clinical trial (DISCOVER-2)","volume":"9","author":"Schett","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.clim.2023.109695_bb0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/annrheumdis-2022-eular.2479","article-title":"Identification of fibrotic and fibrolytic endotypes in rheumatic disease cohorts","volume":"81","author":"Bay-Jensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2023.109695_bb0110","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2023.109695_bb0115","first-page":"A4234","article-title":"Baseline biomarker levels correlate with degree of fibrosis in early ILD, unclassifiable ILD, IPF, advanced IPF, and systemic sclerosis clinical trial cohorts","volume":"203","author":"Sheng","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2023.109695_bb0120","doi-asserted-by":"crossref","first-page":"240ra276","DOI":"10.1126\/scitranslmed.3007096","article-title":"Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis","volume":"6","author":"Zhou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2023.109695_bb0125","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2023.109695_bb0130","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.V94.6.2080","article-title":"Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas","volume":"94","author":"Kossakowska","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clim.2023.109695_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4049\/jimmunol.1301906","article-title":"IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages","volume":"192","author":"Kothari","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2023.109695_bb0140","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3 - a biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.clim.2023.109695_bb0145","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-beta in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2023.109695_bb0150","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann. Rheum. Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623004588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661623004588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:09:14Z","timestamp":1761494954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623004588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"alternative-id":["S1521661623004588"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2023.109695","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2023.109695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Genentech, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109695"}}